达丁强度对移植后耐受性,脂质水平和心脏功能的影响
Dou Huang1, Eric Hirsch2, Kyung Taek Oh3
1From the Division of Cardiology, Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
概括
加剧性他类药物治疗在心脏移植接受者中耐受良好,改善了LDL胆固醇的控制,并保持了心脏功能,没有增加副作用.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类药物对于降低冠状动脉血管病变和心脏移植 (HT) 后死亡率至关重要.
- 强化他类药物治疗方案在HT后保持心脏功能方面的安全性和有效性需要进一步研究.
研究的目的:
- 评估强化类他类药物治疗对心脏功能和心脏移植接受者的脂质水平的耐受性和影响.
主要方法:
- 一项回顾性队列研究分析了277名成年单器官HT接受者 (2012-2021).
- 患者被分为标准强度和强化他类药物组.
- 结果包括他类药物不耐受性,低密度脂蛋白 (LDL) 水平和左心室全球纵向菌株.
主要成果:
- 在标准 (7%) 和强化 (3%) 组 (p=0.56) 之间,他类药物不耐受率相似.
- 强化使用的他类药物在HT后1年保持稳定的LDL水平,与标准使用的他类药物不同,其增加 (p=0.01).
- 接受强化他类药物治疗的患者表现出更好的心肌功能维护,这表明在HT后1-3年内左心室上部全球纵向应变 (p=0.03).
结论:
- 强化他类药物治疗在心脏移植接受者中是安全的,并且耐受良好.
- 高强度的他类药物提供了优越的LDL胆固醇控制,并且与HT后心肌功能保护的改善有关.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Kidney Transplant I: Introduction
339
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
339
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
210
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
210


